Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
146,4 USD | -1,29% | 0,00% | -6,76% |
28/06 | Johnson & Johnson rapporteert 'positieve' resultaten in de late fase van de studie naar myasthenia gravis | MT |
28/06 | Rybrevant-combo van J&J-afdeling krijgt goedkeuring van EU | MT |
Omzet 2024 * | 88,75 mld. 82,86 mld. | Omzet 2025 * | 92,26 mld. 86,14 mld. | Marktkapitalisatie | 352 mld. 328 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 3,96 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,81 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 131.900 |
Dividendrendement 2024 * |
3,3% | Dividendrendement 2025 * |
3,45% | Vrij verhandelbaar | 77,08% |
Recentste transcriptie over Johnson & Johnson
1 dag | -1,29% | ||
3 maanden | -6,76% | ||
6 maanden | -6,76% | ||
Lopend jaar | -6,76% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01-01-89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01-01-98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05-11-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25-04-19 |
D. Davis
BRD | Director/Board Member | 72 | 19-06-14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22-10-09 |
Datum | Koers | Variatie |
---|---|---|
26-06-24 | 148,3 | 0,00% |
28-06-24 | 148,3 | 0,00% |
27-06-24 | 148,3 | 0,00% |
26-06-24 | 148,3 | 0,00% |
25-06-24 | 148,3 | 0,00% |
slotkoers Santiago S.E., 26 juni 2024
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
+55,32% | 815 mld. | |
+44,05% | 641 mld. | |
+13,56% | 314 mld. | |
+10,68% | 303 mld. | |
+16,57% | 242 mld. | |
+13,31% | 218 mld. | |
+8,48% | 168 mld. | |
-2,81% | 159 mld. | |
+0,20% | 120 mld. |